'Cv outcomes' diaporamas de présentation

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus. DPP-4 Inhibitor CV Outcomes Trials in T2DM. T2DM CV Outcomes Trials From the DPP-4 Inhibitor Class. SAVOR-TIMI 53: Primary Endpoint. SAVOR-TIMI 53: Hospitalization for HF. EXAMINE: Primary Endpoint. EXAMINE: Hospitalization for HF.

632 views • 46 slides

Hot topics from the Heart F ailure Congress in Belgrade

498 views • 40 slides

ACE / ARB: renovascular hypertension and nephroprotection

ACE / ARB: renovascular hypertension and nephroprotection. Johan Rosman Renal Physician and CMO Specialist in Hypertension Waitemata DHB, and Apollo Centre , Albany info@bloodpressure.org.nz. Omapere , October 09. A fascinating animal for BP research. Why does a giraffe not faint ?

685 views • 39 slides

Learning Objectives

Learning Objectives. Metabolic Abnormalities Associated With T2D. CV Events With PPAR-gamma Agonists. Effect of Fibrates on CV Outcomes A Systematic Review and Meta-analysis. ACCORD Lipid Hazard Ratios for the Primary Outcome. Pioglitazone Meta-analysis Heart Failure & MI.

505 views • 37 slides

378 views • 27 slides

Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction Robert O. Bonow, MD On behalf of the STICH T

Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction Robert O. Bonow, MD On behalf of the STICH Trial Investigators. STICH Financial Disclosures. Background.

757 views • 26 slides

Hypertension and Updated Guidelines: What is new and what are the take home messages?

Hypertension and Updated Guidelines: What is new and what are the take home messages?. Juan A. Beltran, MD, FACP, FASN Specialist in Clinical Hypertension ASH. Disclosures of Relationships. No disclosures to present. Classification of adult BP (JNC 7). *Isolated Systolic Hypertension

532 views • 24 slides

Hypertension and Updated Guidelines: What is new and what are the take home messages?

Hypertension and Updated Guidelines: What is new and what are the take home messages?. Juan A. Beltran, MD, FACP, FASN Specialist in Clinical Hypertension ASH. Disclosures of Relationships. No disclosures to present. Classification of adult BP (JNC 7). *Isolated Systolic Hypertension

246 views • 24 slides

Calvin Cohen, MD Harvard Medical School CRI New England Boston, MA

Calvin Cohen, MD Harvard Medical School CRI New England Boston, MA. Reexamining the Concept of Stable Therapy: When Should ART Be Adjusted?. Modifying Virologically Suppressive Therapy. First: do no harm Maintain virologic control Maintain CD4 responses

287 views • 17 slides

Diabetes Mellitus 101 for Medical Professionals

Diabetes Mellitus 101 for Medical Professionals. An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes :. Part 5. Stan Schwartz MD,FACP Clinical Associate Professor of Medicine, U of Pa. Cardiometabolic Institute Penn-Presbyterian Hospital,, UPHS.

156 views • 15 slides

Therapy of Type 2 Diabetes Mellitus: UPDATE

Therapy of Type 2 Diabetes Mellitus: UPDATE. Glycemic Goals in the Care of Patients with Type 2 Diabetes- 2013 ADA and AACE Guidelines: Room For Improvement (Be HAPPY/ Avoid Burnout, While Caring for Patients with DM). Stan Schwartz MD, FACP, FACE Affiliate, Main Line Health System

703 views • 14 slides

CAFE, an ASCOT substudy

CAFE, an ASCOT substudy. C onduit A rtery F unction E valuation A nglo- S candinavian C ardiac O utcomes T rial. CAFE, an ASCOT substudy: Objectives. Examine the impact of 2 different BP-lowering regimens on brachial and central aortic blood pressures and other hemodynamic parameters

489 views • 7 slides